{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:20:41Z","timestamp":1784557241032,"version":"3.55.0"},"reference-count":279,"publisher":"Bioscientifica","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["erc.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:p>Prostate and breast cancer are the two cancers with the highest incidence in men and women, respectively. Here, we focus on the known biology of acquired resistance to antihormone therapy of prostate and breast cancer and compare laboratory and clinical similarities in the evolution of the disease. Laboratory studies and clinical observations in prostate and breast cancer demonstrate that cell selection pathways occur during acquired resistance to antihormonal therapy. Following sex steroid deprivation, both prostate and breast cancer models show an initial increased acquired sensitivity to the growth potential of sex steroids. Subsequently, prostate and breast cancer cells either become dependent upon the antihormone treatment or grow spontaneously in the absence of hormones. Paradoxically, the physiologic sex steroids now kill a proportion of selected, but vulnerable, resistant tumor cells. The sex steroid receptor complex triggers apoptosis. We draw parallels between acquired resistance in prostate and breast cancer to sex steroid deprivation. Clinical observations and patient trials confirm the veracity of the laboratory studies. We consider therapeutic strategies to increase response rates in clinical trials of metastatic disease that can subsequently be applied as a preemptive salvage adjuvant therapy. The goal of future advances is to enhance response rates and deploy a safe strategy earlier in the treatment plan to save lives. The introduction of a simple evidence-based enhanced adjuvant therapy as a global healthcare strategy has the potential to control recurrence, reduce hospitalization, reduce healthcare costs and maintain a healthier population that contributes to society.<\/jats:p>","DOI":"10.1530\/erc-17-0416","type":"journal-article","created":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T20:10:27Z","timestamp":1511295027000},"page":"R83-R113","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-1","source":"Crossref","is-referenced-by-count":23,"title":["A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers"],"prefix":"10.1530","volume":"25","author":[{"given":"Philipp Y","family":"Maximov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balkees","family":"Abderrahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona F","family":"Curpan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef M","family":"Hawsawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V Craig","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"2018011617102087000_25.2.R83.1","unstructured":"Abderrahman B Jordan VC 2016 Improving long-term adjuvant anti-oestrogenic therapy for breast cancer. Clinical Pharmacist. (https:\/\/doi.org\/10.1211\/CP.2016.20201203)"},{"key":"2018011617102087000_25.2.R83.2","unstructured":"Abderrahman B Jordan VC 2017 Rethinking extended adjuvant antiestrogen therapy to increase survivorship in breast cancer. JAMA Oncology [epub]. (https:\/\/doi.org\/10.1001\/jamaoncol.2017.351)"},{"key":"2018011617102087000_25.2.R83.3","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.1987.5.6.912","article-title":"Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer","volume":"5","author":"Ahmann","year":"1987","journal-title":"Journal of Clinical Oncology"},{"key":"2018011617102087000_25.2.R83.4","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930501)71:9<2782::AID-CNCR2820710916>3.0.CO;2-Z"},{"key":"2018011617102087000_25.2.R83.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.2330"},{"key":"2018011617102087000_25.2.R83.6","doi-asserted-by":"crossref","first-page":"e0150977","DOI":"10.1371\/journal.pone.0150977","article-title":"Prior adjuvant tamoxifen treatment in breast cancer is linked to increased AIB1 and HER2 expression in metachronous contralateral breast cancer","volume":"11","author":"Alkner","year":"2016","journal-title":"PLoS ONE"},{"key":"2018011617102087000_25.2.R83.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.04.027"},{"key":"2018011617102087000_25.2.R83.8","doi-asserted-by":"publisher","DOI":"10.1038\/219277a0"},{"key":"2018011617102087000_25.2.R83.9","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr257"},{"key":"2018011617102087000_25.2.R83.10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70075-X"},{"key":"2018011617102087000_25.2.R83.11","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000139320.78673.2a"},{"key":"2018011617102087000_25.2.R83.12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1115188108"},{"key":"2018011617102087000_25.2.R83.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2013.11.012"},{"key":"2018011617102087000_25.2.R83.14","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/nrurol.2016.212","article-title":"Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide","volume":"13","author":"Attard","year":"2016","journal-title":"Nature Reviews Urology"},{"key":"2018011617102087000_25.2.R83.15","doi-asserted-by":"publisher","DOI":"10.1002\/pros.21507"},{"key":"2018011617102087000_25.2.R83.16","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.3892\/ijo.2014.2345","article-title":"Prostate cancer: prognostic significance of the association of heterogeneous nuclear ribonucleoprotein K and androgen receptor expression","volume":"44","author":"Barboro","year":"2014","journal-title":"International Journal of Oncology"},{"key":"2018011617102087000_25.2.R83.17","doi-asserted-by":"publisher","DOI":"10.1016\/0960-0760(94)90131-7"},{"key":"2018011617102087000_25.2.R83.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109653"},{"key":"2018011617102087000_25.2.R83.19","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s10549-017-4199-3","article-title":"A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer","volume":"163","author":"Baselga","year":"2017","journal-title":"Breast Cancer Research and Treatment"},{"key":"2018011617102087000_25.2.R83.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09088-8"},{"key":"2018011617102087000_25.2.R83.21","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0140-6736(01)72307-0","article-title":"On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases","volume":"2","author":"Beatson","year":"1896","journal-title":"Lancet"},{"key":"2018011617102087000_25.2.R83.22","doi-asserted-by":"publisher","DOI":"10.2217\/fon.12.49"},{"key":"2018011617102087000_25.2.R83.23","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s10549-013-2814-5","article-title":"Everolimus plus exemestane as first-line therapy in HR(+), HER2(\u2212) advanced breast cancer in BOLERO-2","volume":"143","author":"Beck","year":"2014","journal-title":"Breast Cancer Research and Treatment"},{"key":"2018011617102087000_25.2.R83.24","doi-asserted-by":"publisher","DOI":"10.1210\/en.142.2.838"},{"key":"2018011617102087000_25.2.R83.25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-0433-03"},{"key":"2018011617102087000_25.2.R83.26","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.jmgm.2008.08.001","article-title":"Molecular basis of agonicity and antagonicity in the androgen receptor studied by molecular dynamics simulations","volume":"27","author":"Bisson","year":"2008","journal-title":"Journal of Molecular Graphics"},{"key":"2018011617102087000_25.2.R83.27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0500381102"},{"key":"2018011617102087000_25.2.R83.28","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M507464200"},{"key":"2018011617102087000_25.2.R83.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67101-2"},{"key":"2018011617102087000_25.2.R83.30","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-16-0088"},{"key":"2018011617102087000_25.2.R83.31","doi-asserted-by":"crossref","first-page":"995","DOI":"10.5858\/2000-124-0995-PFIPC","article-title":"Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999","volume":"124","author":"Bostwick","year":"2000","journal-title":"Archives of Pathology and Laboratory Medicine"},{"key":"2018011617102087000_25.2.R83.32","first-page":"1161","article-title":"On oophorectomy in cancer of the breast","volume":"1900","author":"Boyd","year":"1900","journal-title":"British Medical Journal"},{"key":"2018011617102087000_25.2.R83.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052258"},{"key":"2018011617102087000_25.2.R83.34","doi-asserted-by":"publisher","DOI":"10.1210\/endo-100-6-1684"},{"key":"2018011617102087000_25.2.R83.35","doi-asserted-by":"publisher","DOI":"10.1016\/0022-4731(79)90330-3"},{"key":"2018011617102087000_25.2.R83.36","doi-asserted-by":"crossref","first-page":"5953","DOI":"10.1016\/S0021-9258(18)94513-8","article-title":"The intranuclear binding of testosterone and 5-alpha-androstan-17-beta-ol-3-one by rat prostate","volume":"243","author":"Bruchovsky","year":"1968","journal-title":"Journal of Biological Chemistry"},{"key":"2018011617102087000_25.2.R83.37","first-page":"191","article-title":"Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations","volume":"4","author":"Bruchovsky","year":"2000","journal-title":"Molecular Urology"},{"key":"2018011617102087000_25.2.R83.38","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1200\/JCO.2017.72.8808","article-title":"Association between androgen receptor splice variants and prostate cancer resistance to abiraterone and enzalutamide","volume":"35","author":"Bubley","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"2018011617102087000_25.2.R83.39","first-page":"1273","article-title":"Collocation of androgen receptor gene mutations in prostate cancer","volume":"7","author":"Buchanan","year":"2001","journal-title":"Clinical Cancer Research"},{"key":"2018011617102087000_25.2.R83.40","doi-asserted-by":"publisher","DOI":"10.1210\/jc.81.3.1273"},{"key":"2018011617102087000_25.2.R83.41","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-1583"},{"key":"2018011617102087000_25.2.R83.42","doi-asserted-by":"publisher","DOI":"10.1677\/erc.1.00993"},{"key":"2018011617102087000_25.2.R83.43","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-0532"},{"key":"2018011617102087000_25.2.R83.44","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1056\/NEJMe1506680","article-title":"Palbociclib \u2013 taking breast-cancer cells out of gear","volume":"373","author":"Carey","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"2018011617102087000_25.2.R83.45","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-014-3017-4"},{"key":"2018011617102087000_25.2.R83.46","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.268"},{"key":"2018011617102087000_25.2.R83.47","first-page":"2132","article-title":"Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells.","volume":"60","author":"Chen","year":"2000","journal-title":"Cancer Research"},{"key":"2018011617102087000_25.2.R83.48","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1220"},{"key":"2018011617102087000_25.2.R83.49","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(99)80356-2"},{"key":"2018011617102087000_25.2.R83.50","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2347"},{"key":"2018011617102087000_25.2.R83.51","doi-asserted-by":"publisher","DOI":"10.1186\/1423-0127-18-63"},{"key":"2018011617102087000_25.2.R83.52","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2011.02043.x"},{"key":"2018011617102087000_25.2.R83.53","doi-asserted-by":"publisher","DOI":"10.1007\/BF00682741"},{"key":"2018011617102087000_25.2.R83.54","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1200\/JCO.2017.35.15_suppl.503","article-title":"SOLE (Study of Letrozole Extension): a phase III randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women who have received 4\u20136 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer (BC)","volume":"35","author":"Colleoni","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"2018011617102087000_25.2.R83.55","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/S0140-6736(84)92795-8","article-title":"4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer","volume":"2","author":"Coombes","year":"1984","journal-title":"Lancet"},{"key":"2018011617102087000_25.2.R83.56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198908173210702"},{"key":"2018011617102087000_25.2.R83.57","first-page":"5474","article-title":"Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor","volume":"54","author":"Culig","year":"1994","journal-title":"Cancer Research"},{"key":"2018011617102087000_25.2.R83.58","doi-asserted-by":"publisher","DOI":"10.1016\/S0303-7207(02)00263-0"},{"key":"2018011617102087000_25.2.R83.59","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808692"},{"key":"2018011617102087000_25.2.R83.60","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv392"},{"key":"2018011617102087000_25.2.R83.61","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk049"},{"key":"2018011617102087000_25.2.R83.62","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70257-6"},{"key":"2018011617102087000_25.2.R83.63","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaoncol.2015.4406","article-title":"Differing perspectives on breast cancer chemoprevention","volume":"2","author":"Cuzick","year":"2016","journal-title":"JAMA Oncology"},{"key":"2018011617102087000_25.2.R83.64","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60993-8"},{"key":"2018011617102087000_25.2.R83.65","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61963-1"},{"key":"2018011617102087000_25.2.R83.66","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61389-X"},{"key":"2018011617102087000_25.2.R83.67","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014618"},{"key":"2018011617102087000_25.2.R83.68","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0035"},{"key":"2018011617102087000_25.2.R83.69","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-0594"},{"key":"2018011617102087000_25.2.R83.70","doi-asserted-by":"publisher","DOI":"10.1081\/CNV-200032978"},{"key":"2018011617102087000_25.2.R83.71","first-page":"1957","article-title":"Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route","volume":"47","author":"Dowsett","year":"1987","journal-title":"Cancer Research"},{"key":"2018011617102087000_25.2.R83.72","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.1274"},{"key":"2018011617102087000_25.2.R83.73","doi-asserted-by":"publisher","DOI":"10.1021\/jm2000097"},{"key":"2018011617102087000_25.2.R83.74","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61074-1"},{"key":"2018011617102087000_25.2.R83.75","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)11423-4"},{"key":"2018011617102087000_25.2.R83.76","doi-asserted-by":"publisher","DOI":"10.4103\/1008-682X.122876"},{"key":"2018011617102087000_25.2.R83.77","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1204"},{"key":"2018011617102087000_25.2.R83.78","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.04.020"},{"key":"2018011617102087000_25.2.R83.79","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.08.011"},{"key":"2018011617102087000_25.2.R83.80","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.10.001"},{"key":"2018011617102087000_25.2.R83.81","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.08.010"},{"key":"2018011617102087000_25.2.R83.82","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-14-0494"},{"key":"2018011617102087000_25.2.R83.83","doi-asserted-by":"crossref","first-page":"e12792","DOI":"10.7554\/eLife.12792","article-title":"Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation","volume":"5","author":"Fanning","year":"2016","journal-title":"Elife"},{"key":"2018011617102087000_25.2.R83.84","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.17.11.1717"},{"key":"2018011617102087000_25.2.R83.85","unstructured":"FDA 2011 FDA drug safety communication: 5-alpha reductase inhibitors (5-ARIs) may increase the risk of a more serious form of prostate cancer. Rockville, MD, USA: FDA (available at: https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm258314.htm)"},{"key":"2018011617102087000_25.2.R83.86","doi-asserted-by":"publisher","DOI":"10.1038\/35094009"},{"key":"2018011617102087000_25.2.R83.87","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71159-3"},{"key":"2018011617102087000_25.2.R83.88","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji372"},{"key":"2018011617102087000_25.2.R83.89","doi-asserted-by":"publisher","DOI":"10.1038\/sj.pcan.4500982"},{"key":"2018011617102087000_25.2.R83.90","doi-asserted-by":"crossref","first-page":"77071","DOI":"10.18632\/oncotarget.12787","article-title":"Estrogen related receptor alpha in castration-resistant prostate cancer cells promotes tumor progression in bone","volume":"7","author":"Fradet","year":"2016","journal-title":"Oncotarget"},{"key":"2018011617102087000_25.2.R83.91","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(01)01117-7"},{"key":"2018011617102087000_25.2.R83.92","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(84)90043-3"},{"key":"2018011617102087000_25.2.R83.93","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.113R007"},{"key":"2018011617102087000_25.2.R83.94","first-page":"2891","article-title":"Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model","volume":"5","author":"Gleave","year":"1999","journal-title":"Clinical Cancer Research"},{"key":"2018011617102087000_25.2.R83.95","first-page":"4823","article-title":"Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report","volume":"46","author":"Goss","year":"1986","journal-title":"Cancer Research"},{"key":"2018011617102087000_25.2.R83.96","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032312"},{"key":"2018011617102087000_25.2.R83.97","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji250"},{"key":"2018011617102087000_25.2.R83.98","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1604700","article-title":"Extending aromatase-inhibitor adjuvant therapy to 10 years","volume":"375","author":"Goss","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"2018011617102087000_25.2.R83.99","first-page":"5183","article-title":"Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration","volume":"48","author":"Gottardis","year":"1988","journal-title":"Cancer Research"},{"key":"2018011617102087000_25.2.R83.100","first-page":"4090","article-title":"Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens","volume":"49","author":"Gottardis","year":"1989","journal-title":"Cancer Research"},{"key":"2018011617102087000_25.2.R83.101","first-page":"4765","article-title":"Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro","volume":"49","author":"Gottardis","year":"1989","journal-title":"Cancer Research"},{"key":"2018011617102087000_25.2.R83.102","unstructured":"Gray RG Rea D Handley K Bowden SJ Perry P Earl HM Poole CJ Bates T Chetiyawardana S Dewar JA 2013 aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. Journal of Clinical Oncology 31 (15 Supplement) abstract 5. (https:\/\/doi.org\/10.1200\/jco.2013.31.15_suppl.5)"},{"key":"2018011617102087000_25.2.R83.103","first-page":"4315","article-title":"A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy","volume":"61","author":"Gregory","year":"2001","journal-title":"Cancer Research"},{"key":"2018011617102087000_25.2.R83.104","first-page":"2892","article-title":"Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen","volume":"61","author":"Gregory","year":"2001","journal-title":"Cancer Research"},{"key":"2018011617102087000_25.2.R83.105","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116691"},{"key":"2018011617102087000_25.2.R83.106","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.04.012"},{"key":"2018011617102087000_25.2.R83.107","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10565-016-9365-6","article-title":"Tamoxifen resistance and metastasis of human breast cancer cells were mediated by the membrane-associated estrogen receptor ER-alpha36 signaling in vitro","volume":"33","author":"Gu","year":"2017","journal-title":"Cell Biology and Toxicology"},{"key":"2018011617102087000_25.2.R83.108","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.currproblcancer.2016.09.004","article-title":"Targeting the androgen receptor in triple-negative breast cancer","volume":"40","author":"Gucalp","year":"2016","journal-title":"Current Problems in Cancer"},{"key":"2018011617102087000_25.2.R83.109","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1211"},{"key":"2018011617102087000_25.2.R83.110","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197010)26:4<737::AID-CNCR2820260402>3.0.CO;2-T"},{"key":"2018011617102087000_25.2.R83.111","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.4368.393"},{"key":"2018011617102087000_25.2.R83.112","first-page":"149","article-title":"Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome","volume":"63","author":"Hara","year":"2003","journal-title":"Cancer Research"},{"key":"2018011617102087000_25.2.R83.113","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.1999.17.5.1474","article-title":"Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer","volume":"17","author":"Harvey","year":"1999","journal-title":"Journal of Clinical Oncology"},{"key":"2018011617102087000_25.2.R83.114","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S1470-2045(16)30227-3","article-title":"HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study","volume":"17","author":"Hearn","year":"2016","journal-title":"Lancet Oncology"},{"key":"2018011617102087000_25.2.R83.115","doi-asserted-by":"publisher","DOI":"10.1177\/1758834009356433"},{"key":"2018011617102087000_25.2.R83.116","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/89.11.803"},{"key":"2018011617102087000_25.2.R83.117","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/oxfordjournals.annonc.a058286","article-title":"Response after withdrawal of tamoxifen and progestogens in advanced breast cancer","volume":"3","author":"Howell","year":"1992","journal-title":"Annals of Oncology"},{"key":"2018011617102087000_25.2.R83.118","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.10.057"},{"key":"2018011617102087000_25.2.R83.119","first-page":"293","article-title":"Studies on prostatic cancer - I The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"1","author":"Huggins","year":"1941","journal-title":"Cancer Research"},{"key":"2018011617102087000_25.2.R83.120","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-009-0624-6"},{"key":"2018011617102087000_25.2.R83.121","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198101013040104"},{"key":"2018011617102087000_25.2.R83.122","first-page":"5310","article-title":"Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells.","volume":"58","author":"Jarrard","year":"1998","journal-title":"Cancer Research"},{"key":"2018011617102087000_25.2.R83.123","first-page":"387","article-title":"Basic guides to the mechanism of estrogen action","volume":"18","author":"Jensen","year":"1962","journal-title":"Recent Progress in Hormone Research"},{"key":"2018011617102087000_25.2.R83.124","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2332"},{"key":"2018011617102087000_25.2.R83.125","doi-asserted-by":"publisher","DOI":"10.1016\/0303-7207(92)90104-E"},{"key":"2018011617102087000_25.2.R83.126","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-0760(00)00076-5"},{"key":"2018011617102087000_25.2.R83.127","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2964(76)90030-X"},{"key":"2018011617102087000_25.2.R83.128","unstructured":"Jordan VC 1978 DMBA-induced rat mammary carcinoma system for the evaluation of tamoxifen treatment as a potential adjuvant therapy. Reviews on Endocrine-Related Cancer (October Supplement) 49\u201355."},{"key":"2018011617102087000_25.2.R83.129","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0031-6997(25)06650-5","article-title":"Biochemical pharmacology of antiestrogen action","volume":"36","author":"Jordan","year":"1984","journal-title":"Pharmacological Reviews"},{"key":"2018011617102087000_25.2.R83.130","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/oxfordjournals.annonc.a057995","article-title":"Prolonged adjuvant tamoxifen: a beginning not the end","volume":"2","author":"Jordan","year":"1991","journal-title":"Annals of Oncology"},{"key":"2018011617102087000_25.2.R83.131","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1031"},{"key":"2018011617102087000_25.2.R83.132","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706399"},{"key":"2018011617102087000_25.2.R83.133","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.5190"},{"key":"2018011617102087000_25.2.R83.134","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju296"},{"key":"2018011617102087000_25.2.R83.135","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-14-0092"},{"key":"2018011617102087000_25.2.R83.136","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-14-0448"},{"key":"2018011617102087000_25.2.R83.137","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/bcp.12440","article-title":"Proven value of translational research with appropriate animal models to advance breast cancer treatment and save lives: the tamoxifen tale","volume":"79","author":"Jordan","year":"2015","journal-title":"British Journal of Clinical Pharmacology"},{"key":"2018011617102087000_25.2.R83.138","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaoncol.2015.3906","article-title":"Differing perspectives on breast cancer chemoprevention","volume":"2","author":"Jordan","year":"2016","journal-title":"JAMA Oncology"},{"key":"2018011617102087000_25.2.R83.139","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-17-0026"},{"key":"2018011617102087000_25.2.R83.140","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jamaoncol.2017.2074","article-title":"Concerns about methodology of a trial investigating vaginal health during aromatase inhibitor therapy for breast cancer.","volume":"3","author":"Jordan","year":"2017","journal-title":"JAMA Oncology"},{"key":"2018011617102087000_25.2.R83.141","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2964(75)90119-X"},{"key":"2018011617102087000_25.2.R83.142","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2964(80)90156-5"},{"key":"2018011617102087000_25.2.R83.143","unstructured":"Jordan VC Dix CJ Allen KE 1979 The effectiveness of long term tamoxifen treatment in a laboratory model for adjuvant hormone therapy of breast cancer. In Adjuavnt Therapy of Cancer II, pp 19\u201326. Eds Salmon SE Jones SE . New York, NY, USA: Grune and Strattin."},{"key":"2018011617102087000_25.2.R83.144","first-page":"30","article-title":"Anti-oestrogen action in experimental breast cancer","volume":"71","author":"Jordan","year":"1980","journal-title":"Recent Results in Cancer Research"},{"key":"2018011617102087000_25.2.R83.145","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/83.20.1488"},{"key":"2018011617102087000_25.2.R83.146","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv075"},{"key":"2018011617102087000_25.2.R83.147","first-page":"411","article-title":"Sex steroid induced apoptosis as a rational strategy to treat anti-hormone resistant breast and prostate cancer","volume":"21","author":"Jordan","year":"2016","journal-title":"Discovery Medicine"},{"key":"2018011617102087000_25.2.R83.148","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2004.09.041"},{"key":"2018011617102087000_25.2.R83.149","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1200\/JCO.1999.17.5.1499","article-title":"Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer","volume":"17","author":"Kattan","year":"1999","journal-title":"Journal of Clinical Oncology"},{"key":"2018011617102087000_25.2.R83.150","first-page":"4355","article-title":"Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens","volume":"47","author":"Katzenellenbogen","year":"1987","journal-title":"Cancer Research"},{"key":"2018011617102087000_25.2.R83.151","doi-asserted-by":"publisher","DOI":"10.1002\/pros.21107"},{"key":"2018011617102087000_25.2.R83.152","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(196512)18:12<1551::AID-CNCR2820181206>3.0.CO;2-1"},{"key":"2018011617102087000_25.2.R83.153","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2011.02799.x"},{"key":"2018011617102087000_25.2.R83.154","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/jamaoncol.2016.3138","article-title":"Intermittent androgen deprivation therapy-an important treatment option for prostate cancer","volume":"2","author":"Klotz","year":"2016","journal-title":"JAMA Oncology"},{"key":"2018011617102087000_25.2.R83.155","first-page":"1566","article-title":"Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation.","volume":"54","author":"Kokontis","year":"1994","journal-title":"Cancer Research"},{"key":"2018011617102087000_25.2.R83.156","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.383"},{"key":"2018011617102087000_25.2.R83.157","doi-asserted-by":"publisher","DOI":"10.1016\/0022-4731(86)90319-5"},{"key":"2018011617102087000_25.2.R83.158","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1210\/me.2016-1072","article-title":"Minireview: the link between ERalpha corepressors and histone deacetylases in tamoxifen resistance in breast cancer","volume":"30","author":"Legare","year":"2016","journal-title":"Molecular Endocrinology"},{"key":"2018011617102087000_25.2.R83.159","doi-asserted-by":"publisher","DOI":"10.1177\/1534735416658954"},{"key":"2018011617102087000_25.2.R83.160","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.146"},{"key":"2018011617102087000_25.2.R83.161","first-page":"4177","article-title":"Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture","volume":"50","author":"Lerner","year":"1990","journal-title":"Cancer Research"},{"key":"2018011617102087000_25.2.R83.162","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji400"},{"key":"2018011617102087000_25.2.R83.163","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2004.12.032"},{"key":"2018011617102087000_25.2.R83.164","doi-asserted-by":"publisher","DOI":"10.1126\/science.275.5308.1943"},{"key":"2018011617102087000_25.2.R83.165","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.121173298"},{"key":"2018011617102087000_25.2.R83.166","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197402)33:2<503::AID-CNCR2820330227>3.0.CO;2-L"},{"key":"2018011617102087000_25.2.R83.167","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-5997"},{"key":"2018011617102087000_25.2.R83.168","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1348"},{"key":"2018011617102087000_25.2.R83.169","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.0450531"},{"key":"2018011617102087000_25.2.R83.170","first-page":"944","article-title":"Androgen receptor mutations in prostate cancer","volume":"60","author":"Marcelli","year":"2000","journal-title":"Cancer Research"},{"key":"2018011617102087000_25.2.R83.171","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013500"},{"key":"2018011617102087000_25.2.R83.172","doi-asserted-by":"publisher","DOI":"10.1210\/jc.80.10.2918"},{"key":"2018011617102087000_25.2.R83.173","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm568"},{"key":"2018011617102087000_25.2.R83.174","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2174\/1574884711308020006","article-title":"The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice","volume":"8","author":"Maximov","year":"2013","journal-title":"Current Clinical Pharmacology"},{"key":"2018011617102087000_25.2.R83.175","unstructured":"McGuire WL Carbone PP Vollmer EP , United States National Cancer Institute & Breast Cancer Treatment Committee 1975 Estrogen Receptors in Human Breast Cancer. New York: Raven Press."},{"key":"2018011617102087000_25.2.R83.176","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/jamaoncol.2016.3904","article-title":"Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: a randomized clinical trial","volume":"3","author":"Melisko","year":"2017","journal-title":"JAMA Oncology"},{"key":"2018011617102087000_25.2.R83.177","unstructured":"Miller TW 2013 Endocrine resistance: what do we know? American Society of Clinical Oncology Educational Book. (https:\/\/doi.org\/10.1200\/EdBook_AM.2013.33.e37)"},{"key":"2018011617102087000_25.2.R83.178","doi-asserted-by":"crossref","first-page":"44388","DOI":"10.18632\/oncotarget.6317","article-title":"Estrogen and estrogen receptor alpha promotes malignancy and osteoblastic tumorigenesis in prostate cancer","volume":"6","author":"Mishra","year":"2015","journal-title":"Oncotarget"},{"key":"2018011617102087000_25.2.R83.179","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3581"},{"key":"2018011617102087000_25.2.R83.180","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.05.006"},{"key":"2018011617102087000_25.2.R83.181","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-0760(02)00064-X"},{"key":"2018011617102087000_25.2.R83.182","doi-asserted-by":"publisher","DOI":"10.1210\/endo-91-2-427"},{"key":"2018011617102087000_25.2.R83.183","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.76"},{"key":"2018011617102087000_25.2.R83.184","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.01891-08"},{"key":"2018011617102087000_25.2.R83.185","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0913"},{"key":"2018011617102087000_25.2.R83.186","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","article-title":"Treating cancer with selective CDK4\/6 inhibitors","volume":"13","author":"O\u2019Leary","year":"2016","journal-title":"Nature Reviews Clinical Oncology"},{"key":"2018011617102087000_25.2.R83.187","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s10637-015-0235-5","article-title":"AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer \u2013 results of two parallel first-in-human phase I studies","volume":"33","author":"Omlin","year":"2015","journal-title":"Investigational New Drugs"},{"key":"2018011617102087000_25.2.R83.188","first-page":"1061","article-title":"Combination of adjuvant radiotherapy and androgen deprivation therapy after radical prostatectomy in high risk prostate cancer patients \u2013 results from retrospective analysis","volume":"20","author":"Omrcen","year":"2015","journal-title":"Journal of BUON"},{"key":"2018011617102087000_25.2.R83.189","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(87)90154-4"},{"key":"2018011617102087000_25.2.R83.190","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.10.058"},{"key":"2018011617102087000_25.2.R83.191","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/95.5.353"},{"key":"2018011617102087000_25.2.R83.192","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2010.000107"},{"issue":"15 Supplement","key":"2018011617102087000_25.2.R83.193","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1200\/JCO.2016.34.15_suppl.505","article-title":"Predictors of recurrence during years 5-14 in 46,138 women with ER+ breast cancer allocated 5 years only of endocrine therapy (ET)","volume":"34","author":"Pan","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"2018011617102087000_25.2.R83.194","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"2018011617102087000_25.2.R83.195","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2008.07.012"},{"key":"2018011617102087000_25.2.R83.196","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-7-88"},{"key":"2018011617102087000_25.2.R83.197","doi-asserted-by":"publisher","DOI":"10.1210\/me.2002-0253"},{"key":"2018011617102087000_25.2.R83.198","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.385"},{"key":"2018011617102087000_25.2.R83.199","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006185805079"},{"key":"2018011617102087000_25.2.R83.200","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.9285"},{"key":"2018011617102087000_25.2.R83.201","first-page":"1031","article-title":"Cytoplasmic p21WAF1\/CIP1 correlates with Akt activation and poor response to tamoxifen in breast cancer","volume":"28","author":"Perez-Tenorio","year":"2006","journal-title":"International Journal of Oncology"},{"key":"2018011617102087000_25.2.R83.202","first-page":"1809","article-title":"Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience","volume":"10","author":"Pether","year":"2003","journal-title":"Canadian Journal of Urology"},{"key":"2018011617102087000_25.2.R83.203","doi-asserted-by":"crossref","unstructured":"Phallen J Sausen M Adleff V Leal A Hruban C White J Anagnostou V Fiksel J Cristiano S Papp E 2017 Direct detection of early-stage cancers using circulating tumor DNA. Science Translational Medicine 9.","DOI":"10.1126\/scitranslmed.aan2415"},{"key":"2018011617102087000_25.2.R83.204","first-page":"2583","article-title":"An estrogen-independent MCF-7 breast cancer cell line which contains a novel 80-kilodalton estrogen receptor-related protein","volume":"55","author":"Pink","year":"1995","journal-title":"Cancer Research"},{"key":"2018011617102087000_25.2.R83.205","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk050"},{"key":"2018011617102087000_25.2.R83.206","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2010.11.003"},{"key":"2018011617102087000_25.2.R83.207","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0185"},{"issue":"15 Supplement","key":"2018011617102087000_25.2.R83.208","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/jco.2012.30.15_suppl.4548","article-title":"A phase I study of the androgen signaling inhibitor ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"30","author":"Rathkopf","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"2018011617102087000_25.2.R83.209","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.1684"},{"key":"2018011617102087000_25.2.R83.210","doi-asserted-by":"publisher","DOI":"10.1677\/erc.1.01026"},{"key":"2018011617102087000_25.2.R83.211","first-page":"1026","article-title":"Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen","volume":"48","author":"Ravdin","year":"1988","journal-title":"Cancer Research"},{"key":"2018011617102087000_25.2.R83.212","doi-asserted-by":"publisher","DOI":"10.1016\/0022-4731(79)90281-4"},{"key":"2018011617102087000_25.2.R83.213","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/jamaoncol.2016.3934","article-title":"Vaginal estrogens and aromatase inhibitors: how safe is safe enough?","volume":"3","author":"Reeder-Hayes","year":"2017","journal-title":"JAMA Oncology"},{"key":"2018011617102087000_25.2.R83.214","doi-asserted-by":"publisher","DOI":"10.1016\/S0083-6729(05)71007-4"},{"key":"2018011617102087000_25.2.R83.215","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2795"},{"key":"2018011617102087000_25.2.R83.216","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1016\/S0140-6736(16)32389-3","article-title":"Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial","volume":"388","author":"Robertson","year":"2016","journal-title":"Lancet"},{"key":"2018011617102087000_25.2.R83.217","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2823"},{"key":"2018011617102087000_25.2.R83.218","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.05.001"},{"key":"2018011617102087000_25.2.R83.219","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/pros.10356","article-title":"Gain of androgen receptor gene copies in primary prostate cancer due to X chromosome polysomy","volume":"59","author":"Ropke","year":"2004","journal-title":"Prostate"},{"key":"2018011617102087000_25.2.R83.220","doi-asserted-by":"publisher","DOI":"10.1081\/CNV-100103134"},{"key":"2018011617102087000_25.2.R83.221","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11864-017-0473-1","article-title":"Adjuvant endocrine therapy in breast cancer: evolving paradigms in premenopausal women","volume":"18","author":"Rossi","year":"2017","journal-title":"Current Treatment Options in Oncology"},{"key":"2018011617102087000_25.2.R83.222","doi-asserted-by":"publisher","DOI":"10.1210\/er.20.1.22"},{"key":"2018011617102087000_25.2.R83.223","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-2350"},{"key":"2018011617102087000_25.2.R83.224","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198109033051003"},{"key":"2018011617102087000_25.2.R83.225","doi-asserted-by":"publisher","DOI":"10.1677\/erc.0.0100111"},{"key":"2018011617102087000_25.2.R83.226","doi-asserted-by":"publisher","DOI":"10.1210\/er.2008-0016"},{"key":"2018011617102087000_25.2.R83.227","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2008.11.020"},{"key":"2018011617102087000_25.2.R83.228","doi-asserted-by":"publisher","DOI":"10.1016\/0960-0760(96)00018-0"},{"key":"2018011617102087000_25.2.R83.229","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0015-0282(16)38580-6","article-title":"Hypothalamic follicle-stimulating hormone (FSH) and luteinizing hormone (LH)-regulating hormone: structure, physiology, and clinical studies","volume":"22","author":"Schally","year":"1971","journal-title":"Fertility and Sterility"},{"key":"2018011617102087000_25.2.R83.230","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0015-0282(16)38580-6","article-title":"Hypothalamic follicle-stimulating hormone (FSH) and luteinizing hormone (LH)-regulating hormone: structure, physiology, and clinical studies","volume":"22","author":"Schally","year":"1971","journal-title":"Fertility and Sterility"},{"key":"2018011617102087000_25.2.R83.231","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K"},{"key":"2018011617102087000_25.2.R83.232","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60172-9"},{"key":"2018011617102087000_25.2.R83.233","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-031212"},{"key":"2018011617102087000_25.2.R83.234","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1995.523"},{"key":"2018011617102087000_25.2.R83.235","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.177"},{"key":"2018011617102087000_25.2.R83.236","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3010563"},{"key":"2018011617102087000_25.2.R83.237","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-132-7-200004040-00009"},{"key":"2018011617102087000_25.2.R83.238","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1607529","article-title":"Radiation with or without antiandrogen therapy in recurrent prostate cancer","volume":"376","author":"Shipley","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"2018011617102087000_25.2.R83.239","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh166"},{"key":"2018011617102087000_25.2.R83.240","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21254"},{"key":"2018011617102087000_25.2.R83.241","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.4139"},{"key":"2018011617102087000_25.2.R83.242","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.0494"},{"key":"2018011617102087000_25.2.R83.243","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000447552","article-title":"Clinician-reported barriers to implementing breast cancer chemoprevention in the UK: a qualitative investigation","volume":"19","author":"Smith","year":"2016","journal-title":"Public Health Genomics"},{"key":"2018011617102087000_25.2.R83.244","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1200\/JCO.2016.71.7439","article-title":"Participant-reported symptoms and their effect on long-term adherence in the international breast cancer intervention study I (IBIS I)","volume":"10","author":"Smith","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"2018011617102087000_25.2.R83.245","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/93.22.1714"},{"key":"2018011617102087000_25.2.R83.246","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206818"},{"key":"2018011617102087000_25.2.R83.247","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/oxfordjournals.annonc.a057973","article-title":"Overprolonged adjuvant tamoxifen therapy in breast cancer","volume":"2","author":"Stoll","year":"1991","journal-title":"Annals of Oncology"},{"key":"2018011617102087000_25.2.R83.248","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.42.27645"},{"key":"2018011617102087000_25.2.R83.249","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.2147\/OTT.S104398","article-title":"Combined treatment with everolimus and fulvestrant reversed anti-HER2 resistance in a patient with refractory advanced breast cancer: a case report","volume":"9","author":"Sun","year":"2016","journal-title":"OncoTargets and Therapy"},{"key":"2018011617102087000_25.2.R83.250","doi-asserted-by":"publisher","DOI":"10.1677\/erc.0.0100209"},{"key":"2018011617102087000_25.2.R83.251","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/aps.2014.18","article-title":"Androgen receptor: structure, role in prostate cancer and drug discovery","volume":"36","author":"Tan","year":"2015","journal-title":"Acta Pharmacologica Sinica"},{"key":"2018011617102087000_25.2.R83.252","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.05.026"},{"key":"2018011617102087000_25.2.R83.253","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1106783"},{"key":"2018011617102087000_25.2.R83.254","doi-asserted-by":"publisher","DOI":"10.1308\/003588407X179125"},{"key":"2018011617102087000_25.2.R83.255","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0525"},{"key":"2018011617102087000_25.2.R83.256","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.55.6.1574"},{"key":"2018011617102087000_25.2.R83.257","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.79.5.1658"},{"key":"2018011617102087000_25.2.R83.258","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/cas.12897","article-title":"Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive\/human epidermal growth factor receptor-2-negative primary breast cancer","volume":"107","author":"Tomiguchi","year":"2016","journal-title":"Cancer Science"},{"key":"2018011617102087000_25.2.R83.259","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2822"},{"key":"2018011617102087000_25.2.R83.260","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505270"},{"key":"2018011617102087000_25.2.R83.261","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.21.11802"},{"key":"2018011617102087000_25.2.R83.262","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62312-4"},{"key":"2018011617102087000_25.2.R83.263","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3618"},{"key":"2018011617102087000_25.2.R83.264","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2011.12.019"},{"key":"2018011617102087000_25.2.R83.265","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2015.04.017"},{"key":"2018011617102087000_25.2.R83.266","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1012443107"},{"key":"2018011617102087000_25.2.R83.267","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(87)90062-9"},{"key":"2018011617102087000_25.2.R83.268","doi-asserted-by":"publisher","DOI":"10.1021\/jm00037a002"},{"key":"2018011617102087000_25.2.R83.269","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-84745-5_4"},{"key":"2018011617102087000_25.2.R83.270","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2005.04.014"},{"key":"2018011617102087000_25.2.R83.271","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b01276"},{"key":"2018011617102087000_25.2.R83.272","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.265124"},{"key":"2018011617102087000_25.2.R83.273","first-page":"2028","article-title":"Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice","volume":"6","author":"Yao","year":"2000","journal-title":"Clinical Cancer Research"},{"key":"2018011617102087000_25.2.R83.274","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.10.5527"},{"key":"2018011617102087000_25.2.R83.275","doi-asserted-by":"publisher","DOI":"10.1677\/erc.0.0080249"},{"key":"2018011617102087000_25.2.R83.276","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-0760(03)00366-2"},{"key":"2018011617102087000_25.2.R83.277","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2009.080727"},{"key":"2018011617102087000_25.2.R83.278","doi-asserted-by":"publisher","DOI":"10.1038\/76287"},{"key":"2018011617102087000_25.2.R83.279","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-7-59"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/25\/2\/ERC-17-0416.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1530\/ERC-17-0416","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:54:34Z","timestamp":1784555674000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/erc\/article\/25\/2\/R83-R113\/25180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":279,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.1530\/erc-17-0416","relation":{},"ISSN":["1351-0088","1479-6821"],"issn-type":[{"value":"1351-0088","type":"print"},{"value":"1479-6821","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2]]}}}